Literature DB >> 17118960

Azaspiracid-1 alters the E-cadherin pool in epithelial cells.

Giuseppe Ronzitti1, Philipp Hess, Nils Rehmann, Gian Paolo Rossini.   

Abstract

Azaspiracids cause severe damages in the epithelium of several organs. In this study we have investigated the effects of azaspiracid-1 (AZA-1) on two epithelial cell lines. Nanomolar concentrations of AZA-1 reduced MCF-7 cell proliferation and impaired cell-cell adhesion. AZA-1 altered the cellular pool of the adhesion molecule E-cadherin by inducing a dose- and time-dependent accumulation of an E-cadherin fragment (E-cadherin-related antigen [ECRA(100)]), with a concentration inducing the half-maximal effect (EC(50)) of 0.47nM. The immunological characterization of ECRA(100) revealed that it consists of an E-cadherin molecule lacking the intracellular domain, and these data showed that the effect induced by AZA-1 in MCF-7 cells is undistinguishable from that induced by yessotoxin (YTX) in the same experimental system. A comparison of toxin effects in MCF-7 and Caco 2 cells confirmed that the effects induced by AZA-1 and YTX are undistinguishable in these cells. Treatment of fibroblasts with AZA-1 did not affect the cellular pool of N-cadherin showing that the toxin effect is cadherin-specific. A comparison of the effects induced by AZA-1, YTX, and okadaic acid on F-actin and E-cadherin in MCF-7 and Caco 2 cells showed that 1nM AZA-1 did not cause significant changes in F-actin and that accumulation of ECRA(100) did not correlate with decreased levels of F-actin under our experimental conditions. Matching our results with those available in literature, we notice that, when molecular effects induced by AZA-1 and YTX have been studied in the same in vitro systems, experimental data show that they are undistinguishable in terms of sensitive cellular parameters, effective doses, and kinetics of responses in several cell lines. The possibility that azaspiracids and YTXs might share their molecular mechanism(s) of action in defined biological settings should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118960     DOI: 10.1093/toxsci/kfl167

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  6 in total

1.  Azaspiracid substituent at C1 is relevant to in vitro toxicity.

Authors:  Natalia Vilariño; K C Nicolaou; Michael O Frederick; Eva Cagide; Carmen Alfonso; Eva Alonso; Mercedes R Vieytes; Luis M Botana
Journal:  Chem Res Toxicol       Date:  2008-08-16       Impact factor: 3.739

2.  Total synthesis of (+)-azaspiracid-1. An exhibition of the intricacies of complex molecule synthesis.

Authors:  David A Evans; Lisbet Kvaernø; Travis B Dunn; André Beauchemin; Brian Raymer; Jason A Mulder; Edward J Olhava; Martin Juhl; Katsuji Kagechika; David A Favor
Journal:  J Am Chem Soc       Date:  2008-12-03       Impact factor: 15.419

Review 3.  Marine toxins: chemistry, toxicity, occurrence and detection, with special reference to the Dutch situation.

Authors:  Arjen Gerssen; Irene E Pol-Hofstad; Marnix Poelman; Patrick P J Mulder; Hester J van den Top; Jacob de Boer
Journal:  Toxins (Basel)       Date:  2010-04-23       Impact factor: 4.546

4.  Use of biosensors as alternatives to current regulatory methods for marine biotoxins.

Authors:  Natalia Vilariño; Eva S Fonfría; M Carmen Louzao; Luis M Botana
Journal:  Sensors (Basel)       Date:  2009-11-24       Impact factor: 3.576

5.  Combined Effects of Lipophilic Phycotoxins (Okadaic Acid, Azapsiracid-1 and Yessotoxin) on Human Intestinal Cells Models.

Authors:  Pierre-Jean Ferron; Kevin Dumazeau; Jean-François Beaulieu; Ludovic Le Hégarat; Valérie Fessard
Journal:  Toxins (Basel)       Date:  2016-02-19       Impact factor: 4.546

Review 6.  Azaspiracid shellfish poisoning: a review on the chemistry, ecology, and toxicology with an emphasis on human health impacts.

Authors:  Michael J Twiner; Nils Rehmann; Philipp Hess; Gregory J Doucette
Journal:  Mar Drugs       Date:  2008-05-07       Impact factor: 5.118

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.